# Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL

> **NCT04175587** · PHASE3 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 109 (estimated)

## Conditions studied

- Acute Promyelocytic Leukaemia

## Interventions

- **DRUG:** Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

## Key facts

- **NCT ID:** NCT04175587
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2019-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175587, "Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04175587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*